Characterizing the glioma cell of origin in vivo using MADM, a mouse genetic mosa

使用 MADM（一种小鼠遗传莫萨）表征体内神经胶质瘤细胞的起源

基本信息

批准号：
8460147
负责人：
Hui Zong
金额：
$ 31.99万
依托单位：
UNIVERSITY OF VIRGINIA
依托单位国家：
美国
项目类别：
财政年份：
2010
资助国家：
美国
起止时间：
2010-07-01 至 2015-04-30
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/8460147
关键词：
Address Animal Model Cell Lineage Cell division Cells Characteristics Development Developmental Process Disease Genes Genetic Glioma Gliomagenesis Grant Green Fluorescent Proteins Human Label Laboratories Lead Malignant - descriptor Malignant Neoplasms Malignant neoplasm of brain Medicine Modeling Mus Mutate Mutation Neurofibromatosis 1 Pathway interactions Pharmaceutical Preparations Population Premalignant Property Recruitment Activity Reporting Research Resolution Specificity Staging Stem cells Suppressor Mutations System Testing Therapeutic Therapeutic Intervention Tissues Transgenic Mice Transplantation Tumor Stem Cells Tumor Suppressor Genes Tumor Suppressor Proteins Work base cancer stem cell cell type design effective therapy in vivo mouse model mutant neoplastic cell nerve stem cell novel oligodendrocyte precursor prevent progenitor public health relevance stemness therapeutic target treatment strategy tumor tumor initiation tumorigenesis

项目摘要

DESCRIPTION (provided by applicant): Glioma is the most common type of malignant brain tumor. Despite widespread advances in cancer medicine, this devastating disease remains incurable. Recently, it was reported that gliomas contain a population of tumor stem cells that can form self renewable tumor spheres in culture and re- initiate gliomas after transplantation into immuno-suppressed mice. Targeting these tumor stem cells is an exciting prospect towards a glioma cure. However, critical information required to develop such therapeutic strategies, including the developmental origin of the glioma stem cells, remains unknown. To address the tumor cell of origin problem, it requires the use of glioma animal models that allow the analysis of early-stage pre-malignant tumor cells. Unfortunately, current mouse models cannot provide adequate in vivo resolution for such studies. Our laboratory has developed a new mouse glioma model based on a novel genetic mosaic system termed MADM (Mosaic Analysis with Double Markers, Zong et al Cell 2005). Using MADM, we can generate rare, green fluorescent protein (GFP)-labeled neural stem cells (NSCs) that are double null for two key tumor suppressor genes, p53 and Neurofibromatosis Type 1 (NF1), within an otherwise normal mouse. This approach allows us to analyze the entire course of gliomagenesis with single-cell resolution in vivo. Our preliminary findings show that, although the mutations are generated specifically in NSCs, resulting glioma cells manifest many cellular features of oligodendrocyte precursors (OPCs). Prior to malignancy, OPCs are the only cell lineage that drastically over-expands in the MADM mice. In the glioma tumor mass, OPCs are also the predominant cell type that maintains active cell divisions. When we purify these OPC-like glioma cells they manifest salient glioma stem cell features, including forming renewable tumor spheres, differentiating into multiple cell lineages, and reinitiating gliomas after being transplanted into immuno-suppressed mice. Based on these preliminary results, we will test the following hypothesis: 1) OPCs are the key cell type that initiates and renews gliomagenesis; 2) mutant OPCs can de-differentiate to acquire stem cell properties; and 3) targeting OPCs or their stem-cell characteristics will be effective treatment strategies for gliomas. Our proposed studies will lead to valuable basic understanding of the developmental process of gliomas. The identification of tumor-initiating cells should provide a basis for designing rationale treatment strategies for the cure. Conceptually, our proposed work explores the uncharted territory of tumor initiation, and provides critical groundwork for the refinement of mouse models for mechanistic understanding of human cancers.

描述（由申请人提供）：神经胶质瘤是最常见的恶性脑肿瘤类型。尽管癌症医学取得了广泛进展，但这种毁灭性的疾病仍然无法治愈。最近，据报道，神经胶质瘤含有一群肿瘤干细胞，它们可以在培养物中形成自我更新的肿瘤球，并在移植到免疫抑制小鼠体内后重新启动神经胶质瘤。针对这些肿瘤干细胞是神经胶质瘤治疗的一个令人兴奋的前景。然而，制定此类治疗策略所需的关键信息，包括神经胶质瘤干细胞的发育起源，仍然未知。为了解决肿瘤细胞起源问题，需要使用神经胶质瘤动物模型来分析早期癌前肿瘤细胞。不幸的是，当前的小鼠模型无法为此类研究提供足够的体内分辨率。我们的实验室开发了一种新的小鼠神经胶质瘤模型，该模型基于一种称为 MADM（双标记马赛克分析，Zong et al Cell 2005）的新型遗传镶嵌系统。使用 MADM，我们可以在正常小鼠体内生成罕见的绿色荧光蛋白 (GFP) 标记的神经干细胞 (NSC)，这些细胞对于两个关键肿瘤抑制基因 p53 和 1 型神经纤维瘤病 (NF1) 是双无效的。这种方法使我们能够在体内以单细胞分辨率分析胶质瘤发生的整个过程。我们的初步研究结果表明，虽然突变是在 NSC 中特异性产生的，但产生的神经胶质瘤细胞表现出少突胶质细胞前体 (OPC) 的许多细胞特征。在发生恶性肿瘤之前，OPC 是 MADM 小鼠中唯一急剧过度扩增的细胞谱系。在神经胶质瘤肿瘤块中，OPC 也是维持活跃细胞分裂的主要细胞类型。当我们纯化这些 OPC 样神经胶质瘤细胞时，它们表现出显着的神经胶质瘤干细胞特征，包括形成可再生的肿瘤球、分化为多个细胞谱系，以及在移植到免疫抑制小鼠体内后重新启动神经胶质瘤。基于这些初步结果，我们将检验以下假设：1）OPCs是启动和更新神经胶质瘤发生的关键细胞类型； 2）突变的OPCs可以去分化以获得干细胞特性； 3）针对OPCs或其干细胞特征将是神经胶质瘤的有效治疗策略。我们提出的研究将有助于对神经胶质瘤的发育过程产生有价值的基本了解。肿瘤起始细胞的鉴定应该为设计治愈的基本治疗策略提供基础。从概念上讲，我们提出的工作探索了肿瘤发生的未知领域，并为完善小鼠模型以了解人类癌症的机制提供了关键的基础。